Spectrumedics, a cardiovascular medical device provider, will accelerate the launch of the first homegrown intravascular lithotripsy catheter with the fresh funding.
Intravascular Calcification
Spectrumedics Medical Technology (Shanghai) Co., Ltd. (Chinese: 谱创医疗) announced today the completion of a Series A financing round valued at hundreds of millions of CNY
This round was led by Legend Capital (Chinese: 君联资本). BC Capital (Chinese: 拔萃资本)、Wide Capital (Chinese: 怀德资本) and existing investor Sunmed Capital(Chinese: 旸昀资本) also pumped money into this deal.
The funding will be used to support the ongoing clinical R&D of two shockwave catheter products by updating the technology innovation platform, expanding product pipelines, and improving production capacity.
Spectrumedics, headquartered in Shanghai and founded in 2019, is a medical device company specializing in minimally invasive interventional therapy for cardiovascular diseases. Its main competitor is Sonosemi (Chinese: 赛禾医疗).
Sonico-PX is the first independently developed product of Spectrumedics. It is a patented IVL (intravascular lithotripsy) system consisting of two main components: a semi-compliant balloon catheter with electrohydraulic lithotripsy emitters and a portable control system, which is designed to treat multilevel artery calcification diseases.
The electrohydraulic lithotripsy emitters convert electrical energy into shockwaves which disrupt intimal and medial calcium evenly and harmlessly. The IVL catheter connected to the control system will deliver the specified shockwave dosage per procedure under pre-programed pulse meters. In this way, the intravascular lithotripsy minimizes risk to the non-calcified portions of the vessel.
Sonico-PX underwent the registered clinical trial for peripheral IVL in November 2021 and also started the first clinical trial enrolment for the coronary IVL in December 2021.